20/20 Biolabs is trading 15.7% down at $0.19 amid sharp broad-market and technology selling; no company-specific explanation is confirmed.
- A November 5 reminder about the December 9 special meeting included a proposed reverse-split authorization intended to provide flexibility to regain Nasdaq’s $1.00 minimum bid-price compliance.
- The Nasdaq fell as investors reassessed AI infrastructure regulation and spending concerns; biotech-sector weakness also added context.